Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 Haemodialysis of pyrazinamide in uraemic patients.

Literature DB >> 2612545

Haemodialysis of pyrazinamide in uraemic patients.

C Lacroix¹, A Hermelin, R Guiberteau, C Guyonnaud, J Nouveau, H Duwoos, O Lafont.

Abstract

The pharmacokinetics of PZA during haemodialysis were determined in 6 patients with chronic renal impairment after a single oral dose of 25.7 (1.9) mg.kg-1. The dialysis clearance of PZA and of its metabolites were: pyrazinamide 132 ml.min-1; pyrazinoic acid 121 ml.min-1; 5-hydroxy-pyrazinamide 107 ml.min-1; 5-hydroxy-pyrazinoic acid 118 ml.min-1. The average amount extracted during a dialysis session of 4.1 h was 926 mg after an oral dose of 1700 mg. The high dialysability shows that PZA can properly be administered at the end of each dialysis session in the usual dose of 25 to 30 mg.kg-1.

Entities: Chemical Disease Gene Species

Mesh：

Substances：
Pyrazinamide

Year: 1989 PMID： 2612545 DOI： 10.1007/bf00679791

Source DB: PubMed Journal: Eur J Clin Pharmacol ISSN： 0031-6970 Impact factor: 2.953

15 in total

1. In vitro conversion of pyrazinamide into 5-hydroxypyrazinamide and that of pyrazinoic acid into 5-hydroxypyrazinoic acid by xanthine oxidase from human liver.

Authors: T Yamamoto; Y Moriwaki; S Takahashi; T Hada; K Higashino
Journal: Biochem Pharmacol Date: 1987-10-01 Impact factor: 5.858

2. Identification of 5-hydroxypyrazinamide isolated from urine of subjects given pyrazinamide.

Authors: E Beretta; S Botturi; P Ferrari; G Tuan; L F Zerilli
Journal: J Chromatogr Date: 1987-04-24

3. Supervised six-months treatment of newly diagnosed pulmonary tuberculosis using isoniazid, rifampin, and pyrazinamide with and without streptomycin.

Authors: D E Snider; J Graczyk; E Bek; J Rogowski
Journal: Am Rev Respir Dis Date: 1984-12

4. In vitro biotransformation of pyrazinamide by rat liver: identification of a new metabolite.

Authors: D Pitrè; R M Facino; M Carini; A Carlo
Journal: Pharmacol Res Commun Date: 1981-04

5. Plasma protein binding and distribution characteristics of drugs as indices of their hemodialyzability.

Authors: P R Gwilt; D Perrier
Journal: Clin Pharmacol Ther Date: 1978-08 Impact factor: 6.875

6. Pharmacology of pyrazinamide: metabolic and renal function studies related to the mechanism of drug-induced urate retention.

Authors: I M Weiner; J P Tinker
Journal: J Pharmacol Exp Ther Date: 1972-02 Impact factor: 4.030

7. Pyrazinamide (aldinamide) in the treatment of pulmonary tuberculosis.

Authors: R L YEAGER; W G C MUNROE; F I DESSAU
Journal: Am Rev Tuberc Date: 1952-05

8. A controlled trial of 6 months' chemotherapy in pulmonary tuberculosis. Final report: results during the 36 months after the end of chemotherapy and beyond. British Thoracic Society.

Authors:
Journal: Br J Dis Chest Date: 1984-10

9. Five-year follow-up of a controlled trial of five 6-month regimens of chemotherapy for pulmonary tuberculosis. Hong Kong Chest Service/British Medical Research Council.

Authors:
Journal: Am Rev Respir Dis Date: 1987-12